Candesartan cilexetil: Pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist

Folia Pharmacologica Japonica

Volumn 115, Issue 3, 2000, Pages 151-160

  Inada, Yoshivuki ^a   Naka, Takehiko ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin II receptor blockade; Candesartan cilexetil; Heart failure; Hypertension; Renal dysfunction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HEART FAILURE; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; RAT; REVIEW;

EID: 0034026231     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.115.151     Document Type: Review

References (59)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Kahn KH, Wedel H and Westerling S: Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351, 1755-1762 (1998)
2. Johnston CI: Angiotensin receptor antagonists: Focus on losartan. Lancet 346, 1403-1407 (1995)
3. Fletcher AE, Palmer AJ and Bulpitt CJ: Cough with angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens 12 (Suppl 2), S43-S47 (1994)
4. Furukawa Y, Kishimoto S and Nishikawa K: Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patents issued to Takeda Chemical Industries, Ltd. on July 20, 1982 and October 19, 1982, respectively U.S. Patents 4,340,598 and 4,355,040, Osaka, Japan (1982)
5. Nishikawa K, Shibouta Y, Inada Y, Terashita Z-I, Kawazoe K and Purukawa Y: Nonpeptide angiotensin II receptor antagonists: Pharmacological studies on imidazoleacetic acid derivatives. J Takeda Res Lab 50, 75-98 (1991)
6. Chiu AT, Carini DJ, Johnson AL, McCall DE, Price WA, Thoolen MJMC, Wong PC, Taber RI and Timmermans PBMWM: Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308. Eur J Pharmacol 157, 13-21 (1988)
7. Timmermans PBMWMT, Carini DJ, Chiu AT, Duncia JV, Price WA, Wells GJ, Wong PC, Wexler RR and Johnson AL: Angiotensin II receptor antagonists: from discovery to antihypertensive drugs. Hypertension 18 (Suppl III), HI-136- III-142 (1991)
8. Kubo K, Kohara Y, Imamiya E, Sugiura Y, Inada Y, Furukawa Y, Nishikawa K and Naka T: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 36, 2182-2195 (1993)
9. Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K and Naka T: Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 36, 2343-2349 (1993)
10. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T arid Nishikawa K: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxyl- [ [2'- (lH-tetrazol-5-yl) biphenyl4-yl] methyl] -lH-benz-imidazole-7-carboxylic acid (CV-11974), and its prodrug, ( ±)-1-(cyclohexyloxycarbonyl-oxy) -ethyl 2-ethoxyl- [ [2'- (lH-tetrazol-5yl) biphenyl-4-yl] methyl] -lH-benzimidazole-7-carboxylate (TGV-116). J Pharmacol Exp Ther 266, 114-120 (1993)
11. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T and Nishikawa K: Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new non-peptide All antagonist. Biochem Pharmacol 46, 311-318 (1993)
12. Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K and Naka T: Pharmacological properties of candesartan cilexetil - possible mechanisms of long-lasting antihypertensive action. J Hum Hypertens 13 (Suppl 1), S75-S80 (1999)
13. Vanderheyden PML, Fierens FLP, DeBacker JP, Fraeyman N and Vauquelin G: Distinction between surmountable and insurmountable selective ATI receptor antagonists by use of CHO-K1 cells expressing human angiotensin II ATI receptors. Br J Pharmacol 126, 1057-1065 (1999)
14. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K and Nishikawa K: Candesartan (CV11974) dissociates slowly from the angiotensin ATI receptor. Eur J Pharmacol 319, 137-146 (1997)
15. Fierens F, Vanderheyden PML, DeBacker J-P and Vauquelin G: Binding of the antagonist (3H) cande-sartan to angiotensin II ATI receptor-tranfected Chinese hamster ovary cells. Eur J Pharmacol 367, 413-422 (1999)
16. Morsing P, Adler G, Brandt-Eliassson U, Karp L, Ohlson K, Renberg L, Sjöquist P-O and Abrahamsson T: Mechanistic differences of various ATI-receptor blockers in isolated vessels of different origin. Hypertension 33, 1406-1413 (1999)
17. Fierens FLP, Vanderheyden PML, DeBacker J-P and Vauquelin G: Insurmountable angiotensin ATI receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 372, 199-206 (1999)
18. Gaddum JH, Hameed KA, Hathaway DE and Stephen FF: Quantitative studies on antagonists for 5-hydroxytryptamine. Q J Exp Physiol 40, 49-74 (1955)
19. Kenakin TP: Drug antagonism. In Pharmacologie Analysis of Drug Receptor Interaction. Edited by Kenakin TP, Raven Press, New York, 205-244 (1987)
20. Ito K, Shiomi M and Kito G: Effects of the nonpeptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 18, 69-75 (1995)
21. Champion HC, Bivalacqua TJ, Lambert DG, McNamara DB and Kadowitz PJ: The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat. J Am Soc Nephrol 10(Suppl 11), S95-S97 (1999)
22. Wada T, Inada Y, Sanada T, Ojima M, Shibouta Y, Noda M and Nishikawa K: Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Pharmacol 253, 27-34 (1994)
23. Delacrétaz E, Nussberger J, Biollaz J, Waeber B and Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25, 14-21 (1995)
24. Helin K, Stoll M, Meffert S, Stroth U and Unger T: The role of angiotensin receptors in cardiovascular diseases. Ann Med 29, 23-29 (1997)
25. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE and Dzau VJ: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA, 92, 10663-10667 (1995)
26. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T and Inada M: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathie hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96, 3954-3962 (1997)
27. Shimizu M, Wang Q-D, Sjöquist P-O and Rydén L: Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol 32, 231-238 (1998)
28. Jalowy A, Schulz R, Dorge H, Behrends M and Heusch G: Infarct size reduction by ATI-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in.pigs. J Am Coll Cardiol 32, 1787-1796 (1998)
29. Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T, et al.: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, ( ±) -1- (cyclohexyloxycarbonyloxy) ethyl 2ethoxy-1 - [ [ 2 ' - ( 1 H-tetrazol- 5 -yl ) biphen-yl- 4 -yl ] methyl ] -1 H-benzimidazole- 7 -carboxylate ( TCV116), in various hypertensive rats. J Pharmacol Exp Ther 268, 1540-1547 (1994)
30. Ideishi M, Miura S, Sakai T, Maeda H, Kinoshita A, Sasaguri M, Jimi S and Arakawa K: Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl Rats. Blood Press 3(Suppl 5), 99-104 (1994)
31. Elmfeldt D, George M, Hubner R and Olofsson B: Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 11 (Suppl2),S49-S53 (1997)
32. Heuer HJ, Schöndorfer G and Hogemann AM: Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild and moderate hypertension. J Hum Hypertens iKSuppl 2), S55-S56 (1997)
33. Andersson OK and Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 7, 53-59 (1998)
34. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB and Sweet CS: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25, 1345-1350 (1995)
35. Byyny RL: Antihypertensive efficacy of the angiotensin II ATI-receptor antagonist losartan: Results of a randomized, double-blind, placebocontrolled, parallel-group trial using 24-hour blood pressure monitoring. Blood Press 5 (Suppl 2), 7177 (1996)
36. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI and Nelson EB: Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 155, 405-411 (1995)
37. Weber MA, Neutel JM and Smith DHG: Controlling blood pressure throughout the day: Issues in testing a new anti-hypertensive agent. J Hum Hypertens 9 (Suppl 5), S29-S35 (1995)
38. Azizi M, Nicolet L, Chatellier G, Guyene TT, Hempenius J and Menard J: Is the differentiation of ATI receptor antagonists feasible in normotensive volunteers? J Hypertens 5 (Suppl 4), S116 (1997)
39. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI and Bjornsson TD: Pharmacokinetics of losar-tan. an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58, 641-649 (1995)
40. van Lier JJ, van Heiningen PN and Sunzel M: Absorption, metabolism and excretion of "C-candesartan and "C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 11 (Suppl 2), S27-S28 (1997)
41. Gillis JC and Markham A: Irbesartan; A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 54, 885-902 (1997)
42. Ikeda LS, Harm SC, Arcuri KE, Goldberg AI and Sweet CS: Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 6, 35-43 (1997)
43. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S and Mutschler E: Inhibition of angiotensin II pressorresponse and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy volunteers. J Human Hypertens 11 (Suppl 2),S45-S47 (1997)
44. McConnaughey MM, McConnaughey JS and Ingenito AJ: Practical Considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 39, 547-559 (1999)
45. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthélémy G, Gautret B, et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT 1 subtype receptor angiotensin II receptor antagonist. J Pharmacol Exp Ther 265, 826-834 (1993)
46. Chiu AT, McCall DE, Price WA Jr, Wong PC, Carini DJ, DLmcia JV, Wexler RR, Yoo SE, Johnson AL and Timmermans PB: In vitro pharmacology of DuP 753. Am J Hypertens 4, 282S-287S (1991)
47. Takeda K, Fujita H, Nakamura K, Uchida A, Tanaka M, Itoh H, Nakata T, Sasaki S and Nakagawa M: Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 3 (Suppl 5), 94-98 (1994)
48. Kagoshima T, Masuda J, Sutani T, Sakaguchi Y, Tsuchihashi M, Tsuruta S, Iwano M, Dohi K, Nakamura Y, Konishi N, et al.: Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press 3 (Suppl 5), 89-93 (1994)
49. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, Mizuno T, Ueki K, Tobe K, Kadowaki T, et al.: Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretchmediated cardiomyocyte hypertrophy in vitro. Circulation 89, 2204-2211 (1994)
50. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y and Nishikawa K: Protective effects .of candesartan cilexetil (TGV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19, 1079-1099 (1997)
51. Sugimoto K, Gotoh E, Takasaki I, Ebina T, Iwamoto T, Takizawa T, Shionoiri H and Ishii M: ATI receptor antagonist. TCV-116, does not prevent cardiac hypertrophy in salt-loaded Dahl saltsensitive rats. Clin Exp Pharmacol Physiol 23, 282286 (1996)
52. Nishikimi T, Yamagishi H, Takeuchi K and Takeda T: An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 29, 856-861 (1995)
53. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T and Yanagi S: Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 128, 16 (1994)
54. Tanaka A, Matsumori A, Wang W and Sasayama S: An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myo-carditis. Circulation 90, 2051-2055 (1994)
55. Obata J-E, Nakamura T, Kuroyanagi R, Yoshida Y, Guo D-F and Inagami T: Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 52 (Suppl 63), S229-S231 (1997)
56. Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K and Shibouta Y: Effects of candesartan cilexetil (TCV-116) and enalapril in 5 /6 nephrectomized rats. Kidney Int 52 (Suppl 63), S136-S139 (1997)
57. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, et al.: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24, 195-204 (1994)
58. Wada T, Kanagawa R, Ishimura Y, Inada Y and Nishikawa K: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13, 113-122 (1995)
59. Nakamura T, Obata J, Onizuka M, Kiura H, Ohno S, Yoshida Y, Kawachi H and Shimizu F: Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int 52 (Suppl 63), S226-S228 (1997)